These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1570553)

  • 1. Treatment of acute rejection.
    Adams DH; Neuberger JM
    Semin Liver Dis; 1992 Feb; 12(1):80-8. PubMed ID: 1570553
    [No Abstract]   [Full Text] [Related]  

  • 2. BT563 significantly decreases sIL-2R plasma levels despite acute allograft rejection.
    Mueller AR; Platz KP; Steinmüller T; Nüssler N; Neumann U; Gerlach H; Stoll C; Bechstein WO; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3103-5. PubMed ID: 8962203
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of OKT3 in kidney, pancreas, and liver transplantation.
    D'Alessandro AM; Pirsch JD; Melzer JS; Sollinger HW; Kalayoglu M; Reed A; Knechtle SJ; Belzer FO
    Transplant Proc; 1990 Aug; 22(4):1748-9. PubMed ID: 2117796
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of antilymphocyte induction therapy in liver transplantation.
    Wall WJ
    Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S64-70. PubMed ID: 10431019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppression is not related to the response to steroids in acute liver rejection.
    Bercedo J; Jiménez C; Moreno E; García MA; Palomo JC; Loinaz C; Marcello M; Moreno C; Chamorro A; Manzanera M
    Transplant Proc; 1995 Aug; 27(4):2328-9. PubMed ID: 7652830
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of antilymphocyte induction therapy in liver transplantation: A European perspective.
    Langrehr JM; Neuhaus PJ
    Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S71-84. PubMed ID: 10431020
    [No Abstract]   [Full Text] [Related]  

  • 7. Early rejection prophylaxis in heart transplantation: is cytolytic therapy necessary?
    Renlund DG; O'Connell JB; Bristow MR
    J Heart Transplant; 1989; 8(3):191-3. PubMed ID: 2661767
    [No Abstract]   [Full Text] [Related]  

  • 8. Interleukin-2 receptor antibody therapy.
    Ascher NL
    Liver Transpl Surg; 1997 Nov; 3(6):643-4. PubMed ID: 9404968
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of thymoglobulin induction therapy in the prevention of acute graft rejection episodes following liver transplantation.
    Tchervenkov J; Flemming C; Guttmann RD; des Gachons G
    Transplant Proc; 1997 Nov; 29(7A):13S-15S. PubMed ID: 9366919
    [No Abstract]   [Full Text] [Related]  

  • 10. Human liver allograft rejection: severity, prognosis, and response to treatment.
    McDonald JA; Painter DM; Bell R; Gallagher ND; Sheil AG; McCaughan GW
    Transplant Proc; 1989 Oct; 21(5):3792-3. PubMed ID: 2815283
    [No Abstract]   [Full Text] [Related]  

  • 11. Interleukin-2 receptor antibody versus antithymocyte globulin as part of quadruple induction therapy after orthotopic liver transplantation: a randomized study.
    Langrehr JM; Guckelberger O; Nüssler N; Radtke A; Lemmens HP; Jonas S; Lohmann R; Tullius S; Steinmüller T; Raakow R; Neumann U; Knoop M; Bechstein WO; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3204. PubMed ID: 8962241
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of monoclonal antibodies to T cells (OKT3) for treatment of acute cellular rejection after renal transplantation.
    Birkeland SA; Svendsen V; Rohr N; Hansen BL; Elbirk A; Foged N; Køhler F
    Transplant Proc; 1988 Jun; 20(3):451-4. PubMed ID: 3289183
    [No Abstract]   [Full Text] [Related]  

  • 13. Avenues for acquired immune tolerance.
    Wood KJ; Morris PJ
    Semin Thorac Cardiovasc Surg; 1990 Apr; 2(2):189-97. PubMed ID: 2081227
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute pulmonary insufficiency due to OKT3 therapy.
    Büsing M; Mellert J; Greger B; Hopt UT
    Transplant Proc; 1990 Aug; 22(4):1779-81. PubMed ID: 2117808
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation.
    Steininger R; Mühlbacher F; Hamilton G; Längle F; Gnant M; Popow T; Sautner T; Götzinger P; Wamser P; Stockenhuber F
    Transplant Proc; 1991 Aug; 23(4):2269-71. PubMed ID: 1908154
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunosuppression in cardiac transplantation.
    Rose EA; Addonizio LJ
    Bibl Cardiol; 1988; (43):1-9. PubMed ID: 3067706
    [No Abstract]   [Full Text] [Related]  

  • 17. Interleukin-2 receptor antibody vs ATG for induction immunosuppression after liver transplantation: initial results of a prospective randomized trial.
    Lemmens HP; Langrehr JM; Bechstein WO; Blumhardt G; Keck H; Lüsebrink R; Knoop M; Lohmann R; Tullius S; Lobeck H
    Transplant Proc; 1995 Feb; 27(1):1140-1. PubMed ID: 7878826
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of OKT3 rescue therapy after orthotopic liver transplantation--the University of Nebraska Medical Center experience.
    Wood RP; Shaw BW; Williams L
    Transplant Proc; 1988 Feb; 20(1 Suppl 1):254-9. PubMed ID: 3279616
    [No Abstract]   [Full Text] [Related]  

  • 19. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab.
    Baran DA; Lubitz S; Alvi S; Fallon JT; Kaplan S; Galin I; Correa R; Courtney MC; Chan M; Spielvogel D; Lansman SL; Gass AL
    Transplant Proc; 2004 Dec; 36(10):3164-6. PubMed ID: 15686719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute cellular rejection following liver transplantation: clinical pathologic features and effect on outcome.
    Mor E; Solomon H; Gibbs JF; Holman MJ; Goldstein RM; Husberg BS; Gonwa TA; Klintmalm GB
    Semin Liver Dis; 1992 Feb; 12(1):28-40. PubMed ID: 1570549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.